皮下给予治疗性蛋白的免疫原性——一种机制观点。
Immunogenicity of subcutaneously administered therapeutic proteins--a mechanistic perspective.
机构信息
Department of Pharmaceutical Sciences, SUNY-University at Buffalo, 359 Kapoor Hall, Buffalo, New York, 14214, USA.
出版信息
AAPS J. 2013 Oct;15(4):897-900. doi: 10.1208/s12248-013-9510-6. Epub 2013 Jul 16.
Abstract
The administration of therapeutic proteins via the subcutaneous route (sc) is desired for compliance and convenience, but could be challenging due to perceived immunogenic potential or unwanted immune responses. There are clinical and preclinical data supporting as well as refuting the generalized notion that sc is more immunogenic. We provide a mechanistic perspective of immunogenicity of therapeutic proteins administered via the sc route and discuss strategies and opportunities for novel therapeutic approaches to mitigate immunogenicity.
摘要
通过皮下途径（sc）给药治疗性蛋白，具有顺应性和便利性，但由于潜在的免疫原性或不受欢迎的免疫反应，可能具有挑战性。有临床和临床前数据支持和反驳 sc 更具免疫原性的普遍观点。我们提供了通过 sc 途径给药的治疗性蛋白的免疫原性的机制观点，并讨论了减轻免疫原性的新型治疗方法的策略和机会。
相似文献
1
Immunogenicity of subcutaneously administered therapeutic proteins--a mechanistic perspective.皮下给予治疗性蛋白的免疫原性——一种机制观点。
AAPS J. 2013 Oct;15(4):897-900. doi: 10.1208/s12248-013-9510-6. Epub 2013 Jul 16.
2
In Vivo Effect of Innate Immune Response Modulating Impurities on the Skin Milieu Using a Macaque Model: Impact on Product Immunogenicity.使用猕猴模型研究先天免疫反应调节性杂质对皮肤环境的体内效应：对产品免疫原性的影响。
J Pharm Sci. 2017 Mar;106(3):751-760. doi: 10.1016/j.xphs.2016.11.001. Epub 2016 Dec 4.
3
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins.皮下递送治疗性蛋白相关的免疫原性挑战。
BioDrugs. 2021 Mar;35(2):125-146. doi: 10.1007/s40259-020-00465-4. Epub 2021 Feb 1.
4
Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases.生物和非生物免疫调节疗法对风湿病患者疫苗免疫原性的影响。
Arthritis Res Ther. 2014 Dec 23;16(6):506. doi: 10.1186/s13075-014-0506-0.
5
Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study.阿巴西普皮下注射联合或不联合甲氨蝶呤治疗类风湿关节炎患者的免疫原性、安全性和疗效：一项 III 期、国际、多中心、平行臂、开放性标签研究的结果。
Arthritis Care Res (Hoboken). 2013 May;65(5):718-28. doi: 10.1002/acr.21876.
6
Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges.评估蛋白质免疫原性的小鼠模型：经验与挑战
J Pharm Sci. 2016 May;105(5):1567-1575. doi: 10.1016/j.xphs.2016.02.031. Epub 2016 Apr 1.
7
Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats.新型免疫抑制剂CTLA4Ig（BMS-188667）对大鼠皮下和静脉给药后的剂量比例、绝对生物利用度及免疫原性反应评估
Pharm Res. 1997 Jul;14(7):911-6. doi: 10.1023/a:1012156001831.
8
Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context.治疗性抗体的免疫原性：临床环境中抗药物抗体的监测
Ther Drug Monit. 2017 Aug;39(4):327-332. doi: 10.1097/FTD.0000000000000404.
9
Efficient antigen delivery to the draining lymph nodes is a key component in the immunogenic pathway of the intradermal vaccine.高效地将抗原递送至引流淋巴结是皮内疫苗免疫原性途径的关键组成部分。
J Dermatol Sci. 2016 Apr;82(1):38-45. doi: 10.1016/j.jdermsci.2015.11.008. Epub 2015 Nov 22.
10
Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.治疗性蛋白经皮给药的挑战与机遇。
J Pharm Sci. 2018 May;107(5):1247-1260. doi: 10.1016/j.xphs.2018.01.007. Epub 2018 Jan 11.
引用本文的文献
1
Construction of an Indole-induced Transgenic System and Its Therapeutic Effects on Allergic Rhinitis.吲哚诱导转基因系统的构建及其对变应性鼻炎的治疗作用
Am J Respir Cell Mol Biol. 2025 Aug;73(2):310-321. doi: 10.1165/rcmb.2025-0085OC.
2
Local delivery of an adenosine receptor agonist reduces inflammation associated with contact hypersensitivity.局部递送腺苷受体激动剂可减轻与接触性超敏反应相关的炎症。
Drug Deliv Transl Res. 2025 Mar 8. doi: 10.1007/s13346-025-01831-x.
3
A Physiologically Based Pharmacokinetic Model Relates the Subcutaneous Bioavailability of Monoclonal Antibodies to the Saturation of FcRn-Mediated Recycling in Injection-Site-Draining Lymph Nodes.一种基于生理学的药代动力学模型将单克隆抗体的皮下生物利用度与注射部位引流淋巴结中FcRn介导的再循环饱和联系起来。
Antibodies (Basel). 2024 Aug 15;13(3):70. doi: 10.3390/antib13030070.
4
A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics.一种基于机制性标志物的筛选工具，用于预测生物制品的临床免疫原性。
Commun Med (Lond). 2023 Dec 8;3(1):174. doi: 10.1038/s43856-023-00413-7.
5
An injectable subcutaneous colon-specific immune niche for the treatment of ulcerative colitis.可注射的皮下结肠特异性免疫龛用于溃疡性结肠炎的治疗。
Nat Biomed Eng. 2024 Oct;8(10):1243-1265. doi: 10.1038/s41551-023-01136-9. Epub 2023 Dec 4.
6
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).随机、开放标签、二期、生物标志物研究：新辅助皮下曲妥珠单抗在局部晚期、炎症或早期 HER2 阳性乳腺癌患者中的免疫介导作用机制——Immun-HER 试验（GOIRC-01-2016）。
J Immunother Cancer. 2023 Nov 28;11(11):e007667. doi: 10.1136/jitc-2023-007667.
7
Consensus Statement on the Use of Botulinum Neurotoxin in the Middle East.中东地区肉毒杆菌神经毒素使用共识声明
Clin Cosmet Investig Dermatol. 2023 Oct 17;16:2899-2909. doi: 10.2147/CCID.S420921. eCollection 2023.
8
Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases.自身免疫性风湿性疾病生物治疗中的抗药物抗体
J Clin Med. 2023 May 4;12(9):3271. doi: 10.3390/jcm12093271.
9
An injectable PEG-like conjugate forms a subcutaneous depot and enables sustained delivery of a peptide drug.一种可注射的 PEG 样缀合物可形成皮下储库，并能够持续递送至一种肽类药物。
Biomaterials. 2023 Mar;294:121985. doi: 10.1016/j.biomaterials.2022.121985. Epub 2023 Jan 3.
10
Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96.评估抗体药代动力学作为通过PD-1和CD96双重靶向确定真正疗效的先决条件。
Biomedicines. 2022 Sep 1;10(9):2146. doi: 10.3390/biomedicines10092146.
本文引用的文献
1
Exposure to factor VIII protein in the presence of phosphatidylserine induces hypo-responsiveness toward factor VIII challenge in hemophilia A mice.在存在磷脂酰丝氨酸的情况下暴露于因子 VIII 蛋白可诱导血友病 A 小鼠对因子 VIII 挑战的低反应性。
J Biol Chem. 2013 Jun 14;288(24):17051-6. doi: 10.1074/jbc.C112.396325. Epub 2013 May 6.
2
Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon Beta-1a: potential implications for protein aggregation and immunogenicity.鉴定金属催化氧化的干扰素 β-1a 中的氧化位点和共价交联：对蛋白质聚集和免疫原性的潜在影响。
Mol Pharm. 2013 Jun 3;10(6):2311-22. doi: 10.1021/mp300665u. Epub 2013 May 2.
3
Subcutaneous abatacept for the treatment of rheumatoid arthritis.皮下注射阿巴西普治疗类风湿关节炎。
Rheumatology (Oxford). 2013 Jun;52(6):986-97. doi: 10.1093/rheumatology/ket018. Epub 2013 Mar 5.
4
Specialized role of migratory dendritic cells in peripheral tolerance induction.迁移性树突状细胞在外周耐受诱导中的特异性作用。
J Clin Invest. 2013 Feb;123(2):844-54. doi: 10.1172/JCI65260. Epub 2013 Jan 9.
5
Homeward bound: how do skin dendritic cells find their way into the lymph system?归巢：皮肤树突状细胞如何进入淋巴系统？
J Invest Dermatol. 2012 Apr;132(4):1070-3. doi: 10.1038/jid.2012.39.
6
Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice.天然样的因子 VIII 聚集体在血管性血友病因子缺乏和血友病 A 小鼠中具有免疫原性。
J Pharm Sci. 2012 Jun;101(6):2055-65. doi: 10.1002/jps.23091. Epub 2012 Mar 2.
7
PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice.VIII 因子-磷脂酰肌醇复合物的聚乙二醇化：血友病 A 小鼠的药代动力学和免疫原性。
AAPS J. 2012 Mar;14(1):35-42. doi: 10.1208/s12248-011-9309-2. Epub 2011 Dec 16.
8
Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.皮下注射阿巴西普与静脉注射阿巴西普对比：一项针对甲氨蝶呤反应不足患者的IIIb期非劣效性研究
Arthritis Rheum. 2011 Oct;63(10):2854-64. doi: 10.1002/art.30463.
9
Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).皮下注射重组活化因子 VII（rFVIIa）的安全性和药代动力学。
J Thromb Haemost. 2011 Jun;9(6):1191-9. doi: 10.1111/j.1538-7836.2011.04293.x.
10
Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.抗阿达木单抗抗体的产生与长期随访期间疾病活动度和治疗失败的关系。
JAMA. 2011 Apr 13;305(14):1460-8. doi: 10.1001/jama.2011.406.
Zotero 插件